Here are the DEF 14A proxy statements from Kura Oncology, Inc. (KURA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow KURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KURA filings page.
Kura Oncology has called a virtual 2026 Annual Meeting for June 4, 2026 at 8:30 a.m. Pacific Time to elect three Class III directors and handle key governance votes. Stockholders will vote on ratifying Ernst & Young as auditor, approving executive pay on an advisory basis, and choosing how often to hold future Say-on-Pay votes.
The agenda also includes amendments to the Amended and Restated 2014 Equity Incentive Plan, raising its share reserve to 41,077,686 shares including a 6,500,000‑share increase, and changes to the 2015 Employee Stock Purchase Plan. Only holders of 88,762,704 shares outstanding as of April 6, 2026 may vote, primarily via internet or telephone.